Premium
Exacerbation of lymphomatoid papulosis during rituximab therapy
Author(s) -
McCurdy Olivia,
McCormack Chris,
Ritchie David,
Prince H. Miles
Publication year - 2014
Publication title -
australasian journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.67
H-Index - 53
eISSN - 1440-0960
pISSN - 0004-8380
DOI - 10.1111/ajd.12002
Subject(s) - medicine , lymphomatoid papulosis , rituximab , lymphomatoid granulomatosis , exacerbation , cd20 , concomitant , lymphoproliferative disorders , immunology , lymphoma , dermatology , cd30
We report two cases of lymphomatoid papulosis ( LyP ) occurring in conjunction with B‐ cell lymphoproliferative malignancies where the LyP was exacerbated during rituximab (anti‐ CD20 antibody)‐based therapy. We postulate that the altered B‐ cell cytokine milieu acted to allow an exacerbation of the patient's concomitant T‐ cell disease and discuss the possible mechanisms by which this may have occurred.